Try the new BioModels platform (beta)
BioModels Database logo

BioModels Database


MODEL1604270003 - Sharan2014 - model of anti-VEGF agents to investigate circulating angiogenic factor modulation


The following model is part of the non-curated branch of BioModels Database. While the syntax of the model has been verified, its semantics remains unchecked. Any annotation present in the models is not a product of BioModels' annotators. We are doing our best to incorporate this model into the curated branch as soon as possible. In the meantime, we display only limited metadata here. For further information about the model, please download the SBML file.

 |   |   |  Send feedback
Reference Publication
Publication ID: 25295574
Sharan S, Woo S.
Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.
CPT Pharmacometrics Syst Pharmacol 2014; 3: e139
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.  [more]
Original Model: MODEL1604270003.origin
Submitter: Vijayalakshmi Chelliah
Submission Date: 27 Apr 2016 15:21:01 UTC
Last Modification Date: 27 Apr 2016 17:39:49 UTC
Creation Date: 27 Apr 2016 17:39:49 UTC
Encoders:  Guido Santos
Sharan2014 - model of anti-VEGF agents to investigate circulating angiogenic factor modulation

This is a non-SBML model

This model is not available in SBML yet (the SBML file that is provided here is a dummy SBML model). However, the original ADAPT and Berkeley Madonna file provided in the supplementary material of the paper can be downloaded from the link below: [sharan2014_ADAPT5.txt, sharan2014_Berkeley.txt].

This model is described in the article:

Sharan S, Woo S.
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 8;3:e139.


Circulating angiogenic factors (CAF) like vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and sVEGFR2 have potential as biomarkers for antiangiogenic therapy. The interpretation of changes in CAF is complicated by the dynamic nature of the tumor and host cells emanating CAF in response to VEGF pathway inhibition. We developed a systems pharmacology model of anti-VEGF agents to investigate CAF modulation by tumor and host cells, and the relationship between overall CAF changes in response to sunitinib and antitumor efficacy. This model distinguishes between the tumor cells' contributions from tumor-independent response to therapy and total plasma CAF correlating with antitumor activity. Altered VEGF is more likely to serve as a useful biomarker reflecting tumor responses in cancer patients whose pretreatment VEGF is higher than baseline VEGF in healthy subjects. Our findings provide a mechanistic insight into tumor modulation of angiogenic molecules, and may explain the inconsistent results found in previous biomarker studies.

This model is hosted on BioModels Database and identified by: MODEL1604260003.

To cite BioModels Database, please use: BioModels: Content, Features, Functionality and Use.

To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.